Khan, Mairah T.
Irlam-Jones, Joely J.
Pereira, Ronnie Rodrigues
Lane, Brian
Valentine, Helen R.
Aragaki, Kai
Dyrskjøt, Lars
McConkey, David J.
Hoskin, Peter J.
Choudhury, Ananya
West, Catharine M. L. http://orcid.org/0000-0002-0839-3449
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-17-1-0543)
Article History
Received: 3 September 2020
Revised: 11 February 2021
Accepted: 19 February 2021
First Online: 12 April 2021
Ethics approval and consent to participate
: Patients recruited into the BCON trial consented to the use of any samples collected for future research.<sup>7,53</sup> Research using the samples was approved by the Greater Manchester Research Ethics Committee (ethical approval ref: LREC 09/H1013/24). The studies took place in accordance with the Declaration of Helsinki.
: The mRNA (GSE48075), miRNA (GSE84525) expression and clinical (GSE84525) data are publicly available for the 62 MIBC patients. The BCON NanoString miRNA data are available upon request. miRNA expression data for the 106 bladder cancer patients are available on request.
: D.J.M. received honoraria from Janssen Pharmaceuticals, Bioclin, Rainier and H3 Biomedicine and grant support from Astra-Zeneca.
: This work was supported by Cancer Research UK Manchester Institute studentship (C5759/A27412), Major Centre (C147/A25254) and project grant (C1098/A9437; C2094/A11365) funding. It was also supported by the NIHR Manchester Biomedical Research Centre. D.J.M. is supported by a Department of Defense Peer-Reviewed Cancer Research Program Team Translational Science Award (W81XWH-17-1-0543).